Skip to main content

Table 1 Baseline characteristics and CMR findings

From: Diffuse myocardial fibrosis is subclinical and is associated with impaired myocardial deformation characteristics in systemic lupus erythematosus: a cardiovascular magnetic resonance study

  Controls
N = 23
SLE
N = 23
P value
Female sex, n (%) 22 (92) 22 (92) 1.00
Age, years 42 ± 9 41 ± 9 0.68
Current smokers, n (%) 1 (4) 3 (13) 0.10
Hypertension, n (%) 0 0 -
Diabetes, n (%) 0 0 -
Hyperlipidaemia, n (%) 1 (4) 0 -
BMI, kg/m2 23 ± 3 28 ± 6 < 0.001
SLEDAI (median, IQR) N/A 9 (7-14) -
ESR, mm/hr (median, IQR) N/A 6 (4-9) -
CRP, mg/L (median, IQR) 1 (0-1) 3 (2-6) < 0.001
Hemoglobin, g/L 13 ± 1 12 ± 1 0.37
Duration of SLE, years (median, IRQ) N/A 9 (6-14) -
Duration of DMARDs, years (median, IQR) N/A 7 (4-10) -
LVEDV indexed to BSA, ml/m2 79 ± 15 78 ± 13 0.91
LVESV indexed to BSA, ml/m2 21 ± 5 20 ± 6 0.43
LVEF, % 74 ± 5 72 ± 5 0.17
LV Mass indexed to BSA, g/m2 49 ± 10 46 ± 11 0.21
LA size, mm 26 ± 4 31 ± 5 < 0.001
Mid SA circumferential strain -19.3 ± 1.1 -17.0 ± 1.6 < 0.001
Peak diastolic circumferential strain rate (s-1) 119 ± 15 79 ± 26 < 0.001
Presence of LGE (%) 0 5 (22) -
Volume fraction of LGE > 2SD (%) STIR T2 Ratio 0 2.6 ± 0.2 -
STIR T2 Ratio 1.5 ± 0.1 1.6 ± 0.1 0.06
  1. Continuous data are mean ± SD unless otherwise indicated. BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; IQR, interquartile range; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; SA, short axis; SLEDAI, systemic lupus erythematosus disease activity index; SLE, systemic lupus erythematosus; STIR, short Tau inversion recovery